Get the Stockscreener App
85.49
4.93%
-4.435
Pre-market:
85.31
-0.18
-0.21%
Oruka Therapeutics Inc stock is traded at $85.49, with a volume of 1.29M.
It is down -4.93% in the last 24 hours and down -16.53% over the past month.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
See More
Previous Close:
$89.92
Open:
$88.83
24h Volume:
1.29M
Relative Volume:
1.19
Market Cap:
$5.66B
Revenue:
-
Net Income/Loss:
$-116.25M
P/E Ratio:
-35.75
EPS:
-2.3912
Net Cash Flow:
$-91.19M
1W Performance:
-12.52%
1M Performance:
-16.53%
6M Performance:
+114.26%
1Y Performance:
+459.86%
1-Day Range:
$82.69
$89.18
1-Week Range:
$82.69
$98.29
52-Week Range:
$14.89
$115.52
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
650-606-7910
Address
855 OAK GROVE AVE., MENLO PARK
Compare ORKA vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
85.49 | 5.66B | 0 | -116.25M | -91.19M | -2.3912 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Piper Sandler | Overweight |
| Nov-13-25 | Initiated | Jefferies | Buy |
| Oct-27-25 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Barclays | Overweight |
| May-22-25 | Initiated | BTIG Research | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Oct-11-24 | Initiated | Stifel | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | Leerink Partners | Outperform |
| Sep-16-24 | Initiated | TD Cowen | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
| Oct-09-13 | Initiated | Dawson James | Buy |
View All
Oruka Therapeutics Inc Stock (ORKA) Latest News
Oruka Therapeutics, Inc. (ORKA) stock price, news, quote and history - Yahoo Finance UK
Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says - Yahoo Finance
Oruka Therapeutics, Inc. (ORKA) Stock Price, News, Quote & History - Yahoo! Finance Canada
ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data - TradingView
Oruka Therapeutics stock price target maintained at $120 by H.C. Wainwright - Investing.com Canada
Clear Street Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $131 - Moomoo
What Oruka Therapeutics (ORKA)'s Phase 2a Psoriasis Data Means For Shareholders - Yahoo Finance
Oruka Shares Fall Despite Deepening Week 28 Responses for ORKA-001 - marketscreener.com
Update: Oruka Shares Fall Despite Deepening Week 28 Responses for ORKA-001 - Yahoo Finance
10 Health Care Stocks Whale Activity In Today’s Session - Benzinga
Oruka posts trial data for plaque psoriasis drug (ORKA:NASDAQ) - Seeking Alpha
Oruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacy - AOL.ca
Why is Oruka Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Oruka Therapeutics Reports Deepening Responses for ORKA-001 Through Week 28 - marketscreener.com
Oruka Therapeutics Shares Fall 5% After Week 28 ORKA-001 Trial Data - Yahoo Finance
Oruka Therapeutics stock falls despite positive trial data By Investing.com - Investing.com Australia
Oruka Therapeutics stock falls despite positive trial data - Investing.com
Oruka reports week 28 psoriasis trial results for ORKA-001 By Investing.com - Investing.com Canada
In a psoriasis trial, 71% had clear skin six months after their last dose - Stock Titan
Oruka Therapeutics general counsel Paul Quinlan sells $936k in stock - Investing.com Nigeria
Form 4 Oruka Therapeutics Inc For: 22 September By Investing.com - Investing.com Canada
Form 4 Oruka Therapeutics Inc For: 22 September - Investing.com UK
Details on Warrant Exercise and Subsequent Share Sales by Oruka Therapeutics' General Counsel - Kalkine Media
Oruka Therapeutics SVP Arjun Agarwal Sells 533 Shares Under Rule 10b5-1 Plan - Kalkine Media
Oruka Therapeutics SVP Arjun Agarwal sells $51,034 in ORKA stock By Investing.com - Investing.com South Africa
Oruka Therapeutics SVP Arjun Agarwal sells $51,034 in ORKA stock - Investing.com UK
Oruka Therapeutics Insider Sold Shares Worth $936,417, According to a Recent SEC Filing - marketscreener.com
Oruka Therapeutics (NASDAQ: ORKA) insider plans new share sale after recent 10b5-1 trades - Stock Titan
ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94% - Stocktwits
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A 58.6% Potential Upside Beckons Biotech Investors - DirectorsTalk Interviews
LifeSci Capital Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $175 - Moomoo
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 - PR Newswire
Oruka Therapeutics COO Sandler sells $86,713 in common stock By Investing.com - Investing.com South Africa
Oruka Therapeutics chief medical officer Joana Goncalves sells $734k in shares By Investing.com - Investing.com South Africa
Oruka Therapeutics SVP Agarwal sells over $926k in common stock By Investing.com - Investing.com South Africa
Oruka Therapeutics SVP Agarwal sells over $926k in common stock - Investing.com Canada
Oruka Therapeutics CEO Lawrence Klein sells $234,680 in ORKA stock - Investing.com
Oruka Therapeutics chief medical officer Joana Goncalves sells $734k in shares - Investing.com UK
Oruka Therapeutics general counsel Paul Quinlan sells $99,442 in stock - Investing.com UK
Oruka Therapeutics COO Sandler sells $86,713 in common stock - Investing.com
Oruka Therapeutics CEO Lawrence Klein Executes 2,452-Share Sale for RSU Tax Withholding - Kalkine Media
Oruka Therapeutics SVP Finance Arjun Agarwal Reports Multiple Stock Option Exercises and Sales - Kalkine Media
Oruka Therapeutics to Attend Morgan Stanley Global Healthcare Conference - Bitget
Morgan Stanley's New York healthcare conference includes Oruka - Stock Titan
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference - GlobeNewswire
About Oruka Therapeutics Inc aStock - Coinbase
ORKA News | ORUKA THERAPEUTICS INC (NASDAQ:ORKA) - ChartMill
H.C. Wainwright reiterates Oruka Therapeutics stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Oruka Therapeutics stock rating at buy - Investing.com UK
UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Oruka Therapeutics CEO Klein sells $6.8m in stock By Investing.com - Investing.com South Africa
Oruka Therapeutics Inc Stock (ORKA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):